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Outline 
• Setting the context: socioeconomic 
differentials in all-cause mortality England in: 
• Life expectancy 
• Lifespan variability 
• Morbidity and disability 
• Why CHD? (coronary heart disease) 
• IMPACTsec model and results 
• Next steps 
2 
Index of Multiple Deprivation 2007, England 
(map at district level) 
 
• IMD 2007 combines indicators 
across 7 deprivation domains into 
a single index score 
– Income,  employment,  health,  
education, housing and services, 
crime, and living environment 
• Lowest-level geography IMD 
calculated for 32,482 Lower Super 
Output Areas (LSOAs) in England 
with c. 1,500 people each  
• LSOAs ranked by ascending IMD 
2007 score and grouped into 
population quintiles  
– Q1: Least deprived quintile 
– Q5: Most deprived quintile 
Source: Noble et al (2007) 
Trends in LE@65: 1982-2006 Males 
Area-based deprivation Individual socioeconomic 
status 
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Age 
Mode 
(85y) 
Lifespan dispersion measures 
(Males, E&W, 2010) 
Life expectancy 
(79y) 
5 
Median 
(81y) 
Lifespan variation Q1 v Q5: England 2001 
(deaths pooled 1999-2003, smoothed moving average over 5 years of age)  
 
Men  (aged 25+) Women  (aged 25+) 
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Measure of dispersion Eng Q1 Q5 Q1-Q5 
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Cause of death distribution by age: males 
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Multi-morbidity by age and deprivation deciles 
Scotland, 2007 
 
• Young and middle-aged 
people (25-70y) living in the 
most deprived areas had 
multiple morbidity (2+ 
diseases) rate as high as 
those 10+ years older living 
in most affluent areas 
Karen Barnett et al, Epidemiology of Multi-morbidity, Lancet, 2012 
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Males: Life expectancy with and without disability: at birth and age 65  
by deprivation quintiles England 2007-2010  
(Source: adapted from ONS ‘Inequalities in DFLE, 2013’) 
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To recap.. 
• People in disadvantaged circumstances live 
shorter lives, get diseases earlier and spend 
more years of their (shorter) life with 
disability. 
• Poor and rich die from the same causes, but 
at different rates. 
• There is an inverse social gradient in health – 
each higher social grade has lower rates of ill-
health and death. 
 
 
10 
Why model CHD? 
• Fall in CHD mortality has driven rapid 
improvements in life expectancy over last 25 
years. 
• But it still remains a leading cause of death 
and of persistent inequalities. 
• Model to explain why CHD mortality fell: 
– was it better treatments; or reductions in risk 
factors?  
– did the contributions of these factors differ by 
socioeconomic circumstances? 
 11 
Decline in Deaths from Cardiovascular Disease in Relation to Scientific Advances 
Source: Nabel & Braunwald E, NEJM 2012 
We live in a golden age of medical progress … 
Decline in Deaths from Cardiovascular Disease in Relation to Important Public Health and Primary 
Care:  An alternative view 
N Engl J Med 2012;366:1258-1260. Laing, Katz (letters to Nabel Baumwauld article) 
Age standardised CHD mortality rates by 
deprivation quintiles 1982-2006 
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Average annual percentage fall in age-
standardised CHD mortality rates by 
deprivation and sex 1982-2006 
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15 Modelled estimates of annual % change using JoinPoint 
Average annual percentage change in CHD 
mortality by deprivation 1982-2006 
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Explaining the fall in CHD mortality 
The IMPACT model 1981-2000 (England and Wales) 
-80000
-60000
-40000
-20000
0
Risk Factors worse  +13% 
 Obesity (increase)      +4% 
 Diabetes (increase)     +5% 
 Physical activity (less)  +4% 
Risk Factors better  -71% 
Smoking -41% 
Cholesterol           -9% 
Population BP fall    -9% 
Deprivation           -3% 
Other factors     -8% 
  Treatment      -42% 
AMI treatments        -8% 
Secondary prevention  -11% 
Heart failure  -12% 
CABG & PTCA  -  4% 
Angina: Aspirin etc  -  5% 
Hypertension therapies -3%  
 
 Unal, Critchley & Capewell   Circulation 2004  109(9)  1101  
Incidence CHD : improved population risk factors, & 
detection/treatment high risk individuals 
Case-fatality : better treatments in acute phase, & improved secondary 
prevention 
68,230 fewer 
CHD deaths 
1981 2000 
50%-75% due to 
net risk factor 
reduction 
 
25%-50%: due 
to evidence-
based therapies 
 
IMPACTsec model coverage 
• Coverage: 
– England, total population aged 25+ 
– Period: 2000 (base year) to 2007 (final year) (2) 
– Estimates stratified by age & sex (7*2) 
– SEC as measured by small-area deprivation quintiles 
(IMD07 at LSOA level) (5) 
 
• Risk Factors – 7 (smoking, diabetes, physical 
inactivity; systolic blood pressure (SBP), total 
cholesterol, fruit & veg, BMI) 
 
• 45+ treatments in 9 patient groups (e.g. heart attack 
(N/STEMI), stable angina, heart failure) 
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CHD mortality fall 2007   
by IMD quintiles  
Target Deaths Prevented or Postponed (DPP) = 38,070 19 
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Source: Health Survey for England 
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Summary: Risk factor change by deprivation  
Adults (55+), England 2000 to 2007 
Annual % Δ Men Women 
Significant  
decrease  
across  
all SEC groups 
Smoking  
SBP  
Total cholesterol  
 
Smoking  (~Q4)  
SBP  
Total cholesterol  
 
Significant  
increase  
across all SEC 
groups 
Obesity 
Diabetes  
 
Obesity (~Q2) 
Diabetes  
Mixed picture 
by SEC 
Phys activity increase: Q1-Q3 
Fruit & Veg increase: Q3 
 
Phys activity increase: Q1-Q4 
Fruit & Veg increase: Q3-Q4  
21 Q1 = least deprived; Q5 = most deprived Scholes, SSM 2010 
Change in treatment uptake post-MI: 
males 55-74  
Statins ACE-Inhibitors 
22 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
IMDQ1 IMDQ2 IMDQ3 IMDQ4 IMDQ5 Eng
2000
2007
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
IMDQ1 IMDQ2 IMDQ3 IMDQ4 IMDQ5 Eng
%
 o
f 
e
lig
ib
le
 p
at
ie
n
ts
 
Source: General Practice Research Dataset 
CHD deaths prevented in England  
2000 to 2007 
Risk Factors worse  +  9% 
 BMI (increase)       +  2% 
 Diabetes (increase)     +  7% 
  
Risk Factors better  -43% 
Smoking        -  3% 
Cholesterol           -  6% 
SBP fall     - 29% 
Physical inactivity        -  2% 
Fruit & Veg     -  4%  
Treatments uptake change    -52% 
AMI/NSTEACS -  1% 
2’ post MI    -  9% 
2’ post-revasc  -  2% 
Stable Angina  - 13% 
Heart failure  - 10% 
Hypertension therapies  -  4%  
Hyperlipidemia Rx - 12% 
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(~86% explained) 
2000 2007 
-20k 
-16k 
+3k 
-40'000
-35'000
-30'000
-25'000
-20'000
-15'000
-10'000
-5'000
0
5'000
2 0 2007
Source: Bajekal, Scholes, Love , Hawkins,  
O’Flaherty, Raine, Capewell. Plos Medicine, 2012 
CHD deaths prevented 2007  
affluent  vs deprived areas 
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Source: Bajekal, Scholes, Love , Hawkins, O’Flaherty, Raine, Capewell. Plos Medicine, 2012 
Key strength and limitation of 
English IMPACTsec model 
• First ever trend analysis to examine the socio-
economic dimension of treatment and risk factor 
contributions to falls in CHD mortality. 
• Changes in risk factor levels could not explain 20% 
of observed CHD fall in affluent groups 
– social gradient in effect modification? 
– Imprecision/biases in survey estimates?  
– Synergistic effects? 
– Other ‘upstream’ risk factors – e.g. psychosocial? 
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IMPACTsec: main messages 
• CHD mortality fell by 36% in just 7 years: 
treatments explained approximately half of 
this (52%) and risk factors a third (34%).  
•   in drug prescribing in community, AND 
no inequity in uptake. 
• More lives saved due to bigger  risk factors 
in deprived than affluent areas. 
• But these are partly offset by faster  in 
diabetes & BMI in deprived areas. 
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Implications of findings on future 
trends in total mortality 
• CHD is the leading cause of death and so trends in CHD have 
a major impact on total mortality trends. 
• The relative importance of smoking as a driving force for 
CHD mortality reductions has diminished over the latter part 
of the 20th century. 
• However, this has not led to the (anticipated) reduction in 
the aggregate pace of mortality improvement in CHD or total 
mortality. 
• Better medical management of patients has played/will 
continue to play an important, incremental, role in driving-
up life expectancy in the early 21st century. 
 
28 
Next steps: linked patient records analysis 
• Drilling deeper to look at socio-economic 
inequalities in phenotypes of CHD + Stroke. 
• Survival analysis: descriptive and analytic 
modelling of predictors. 
• Key Q: for which CVD phenotype, and at 
what points along the disease pathway, do 
inequalities widen/remain the same/shrink 
and by how much? 
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With thanks to: 
• The IMPACTsec team:  
– Shaun Scholes, Prof Rosalind Raine (UCL) 
– Prof Simon Capewell, Martin O’Flaherty, Nathaniel 
Hawkins (Univ of Liverpool) 
– Hande Love (L&G) 
• Legal & General Longevity Risk Team  
• Other collaborators: Paul Norman, Andres Villegas 
(CASS), ONS mortality team 
Contact: m.bajekal@ucl.ac.uk 
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Thank you. Any questions? 
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RESERVE SLIDES 
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Model parameters for calculating deaths 
prevented or postponed (DPPs) 
IMPACT is a deterministic model quantifying change between 2 time points. 
 
DPPs due to TREATMENT : (improved survival with CHD) 
• DPPs = Eligible Patients × treatment uptake × relative mortality reduction × one 
year case fatality 
• Net change DPP= DPP final year – DPP base year 
 
DPPs due to POPULATION RISK FACTOR CHANGE: (reduced CHD incidence) 
• DPPs  = expected CHD deaths in 2007 (applying 2000 mortality rates) × risk factor 
change between 2000 and 2007 ×  B-regression coefficient  
• DPPs = expected CHD deaths in 2007 (applying 2000 mortality rates ) × 
(PARF2000 – PARF2007) 
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Population risk factor change 1980/2000:  
Impact on CHD Mortality: example 
3mmHg fall in systolic BP in women aged 55-64 
 
  CHD deaths      Beta  Risk Factor    Deaths  
 in base yr     coefficient  reduction     prevented 
                            1980-2000      or postponed (DPP)  
   a          x     β       x      c     =   a*(1-(EXPβ x c)) 
 
 26,350 x  -0.035 x      3      =  2700 DPP  
 
SOURCES 
    Mortality  Oxford PSC      HSfE 
    statistics      meta-analyses  surveys       
    
   
AMI: Thrombolysis & Aspirin, Men 55-64 years 
 
Patients        Treatment  Relative      Case   Deaths prevented   
eligible          uptake     risk           Fatality      or postponed (DPP)     
                reduction  
 
   a     x  b     x       c    x        d   =    a x b x c x d 
102,280  X  21%  x  0.26  x   0.054   =   303 
SOURCES 
 HES           MINAP   Estess & FTT US/Wijeysundera 
statistics           audits        Meta-analyses   
    
Treating individual CHD patients - impact 
on population CHD mortality: example 
   
β Coefficients = % fall in CHD mortality per 
unit decrease in risk factors  
(from meta-analyses & cohorts , Ford et al, NEJM 2007   356 : 2388  
Cholesterol lowering PSC 2007     Reduction in CHD deaths 
 
 0.1mmol/l mean pop cholesterol   5% 
Fruit & Veg Duchet J Nutrition 2006 
   1 portion/day      4%  
Blood pressure PSC Lancet 2003   
  1 mm Hg Systolic BP      3.5% (log -0.035) 
 
Obesity Bogers, 2008 
   1 Kg/M2 BMI      2.5% 
 
Diabetes InterHEART, 2004 
 1% diabetic population     2% 
Smoking InterHEART, 2004 
  1% Smoking prevalence     1% 
Physical Activity InterHEART, 2004 
  1% inactive population      0.3% 
  Ford et al  NEJM 2007 36 
Females: Life expectancy with and without disability: at birth and age 65, 
by deprivation quintiles, England 2007-2010  
(ONS: Inequalities in DFLE, 2013) 
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